Brian Lian - 27 Mar 2024 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
President & CEO, Director
Signature
/s/ Michael Morneau, as Attorney-in-Fact
Issuer symbol
VKTX
Transactions as of
27 Mar 2024
Transactions value $
-$12,830,026
Form type
4
Filing time
27 Mar 2024, 20:51:31
Previous filing
04 Mar 2024
Next filing
31 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Award $0 +222K +10.08% $0.00 2.42M 27 Mar 2024 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Tax liability -$12.8M -154K -6.36% $83.34 2.27M 27 Mar 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on March 27, 2024 upon the achievement of a non-financial performance goal.
F2 These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units.